AnalytiXIN creates new Indiana healthcare-based consortium to advance data-driven clinical research and improve health outcomes

New shared platform will use consented health data to facilitate life sciences research, advance healthcare, and to engage patients via precision medicine

INDIANAPOLIS (January 21, 2025) – AnalytiXIN today announced the launch of a new consortium to help healthcare organizations across Indiana better identify and access comprehensive, consented clinical and genomic health data. It is a continued investment to improve patient outcomes and drive efficiencies to accelerate clinical research. Access to these diverse datasets will allow researchers to quickly develop and conduct more accurate and personalized studies, enabling more effective healthcare interventions, further establishing Indiana as a leader in health sciences data analytics.

Several leading Indiana-based healthcare companies, including Eli Lilly and Company (“Lilly”), Indiana University (IU) Health, IU School of Medicine, and the Indiana Health Information Exchange (IHIE) have pledged unprecedented commitment to this collaboration.

“We’re excited to work with our AnalytiXIN consortium partners to harness the power of data analytics, with the aim of advancing scientific research and improving health outcomes,” said David A. Ricks, Lilly chair and CEO. “Accurate, comprehensive data will provide our researchers with important new insights that will enhance clinical trial design and enrollment and accelerate the development of innovative new medicines for people here in Indiana and around the world.”

The consortium will serve a broad range of stakeholders, including life sciences researchers, healthcare providers, and data scientists, fostering collaboration to accelerate data-driven clinical research. By bringing together experts in precision medicine, genomics, and data analytics, the consortium will drive innovative research efforts. It will prioritize improving health outcomes, with a focus on cardio-metabolic diseases, neurodegenerative conditions, and other critical health challenges impacting Hoosiers.

"The AnalytiXIN consortium's success depends on Hoosiers joining the Indiana Biobank. Their involvement, along with our partners' expertise, helps us understand treatments tailored to each person's genetics," said Dennis Murphy, president and CEO of IU Health. "With over 60,000 Hoosiers already participating, more people joining will help us prevent and treat diseases, making Indiana one of the healthiest states in the nation."

“The AnalytiXIN consortium is an exciting opportunity to harness the vast resources held within the Indiana Biobank here at the IU School of Medicine, coupled with the depth of data contained in IU Health’s electronic medical records, to help accelerate the discovery of new therapies,” said Jay L. Hess, MD, PhD, MHSA, dean of the IU School of Medicine and IU’s executive vice president for university clinical affairs. “The impact that this collaboration could have on the health of Hoosiers across the state is immeasurable. The School of Medicine is thrilled to be a partner in this groundbreaking effort.”

AnalytiXIN is a strategic program run by the Central Indiana Corporate Partnership (CICP) and is designed to bolster the economic vitality and drive sustained innovation in Indiana by advancing the integration of strategic technologies—artificial intelligence, machine learning, and data analytics—in the life sciences and manufacturing industries, both significant drivers of the state’s economic, social and physical wellbeing. It is funded with support from Lilly Endowment Inc.

“By leveraging this unique life sciences health data asset, we're empowering our partners like Lilly, IU Health, and the IU School of Medicine to accelerate innovation and drive breakthroughs faster and more effectively than ever,” said Melina Kennedy, CEO of the Central Indiana Corporate Partnership. “We invite life sciences industry leaders, health systems, and universities to join us in harnessing this asset to further advance Indiana's leadership in healthcare and life sciences.”

About AnalytiXIN

AnalytiXIN was established through a Lilly Endowment Inc. grant to the Central Indiana Corporate Partnership to develop a digital community, including a place-focused collaboration hub in Indianapolis that will strengthen connections and encourage engagement of academic data science R&D talent with their industry peers to drive sustained innovation within Indiana. The project is intended to grow and enable the digital ecosystem and drive sustained innovation within the State. The emphasis is on life sciences and manufacturing – two of Indiana’s most important and prolific economic drivers. To learn more, visit www.analytixindiana.com.

About Central Indiana Corporate Partnership (CICP)

The Central Indiana Corporate Partnership (CICP) was formed in 1999 to bring together the chief executives of the region’s prominent corporations, foundations and universities in a strategic and collaborative effort dedicated to Indiana’s continued prosperity and growth. To advance this mission, CICP sponsors five key talent and industry sector initiatives, AgriNovus Indiana, Ascend Indiana, BioCrossroads, Conexus Indiana, and TechPoint, each of which addresses challenges and opportunities unique to its respective area: agbiosciences, talent and workforce development, life sciences, advanced manufacturing and logistics, advanced energy technology and transportation and technology. To learn more, visit www.cicpindiana.com.